Virtual Reality Distraction During Arteriovenous Fistula Puncture
The Effect of Virtual Reality Distraction on Pain and Anxiety During Arteriovenous Fistula Puncture Among Hemodialysis Patients: Randomized Controlled Trial
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Mansoura, Egypt
- faculty of nursing Mansoura university
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- patients who are under- going conventional hemodialysis three times a week
- hemodialysis period of one month or more
- having a healthy AVF access with good function
- welling to participate in study
Exclusion Criteria:
- patients who have psychiatric diseases
- panic disorder, anxiety disorder
- dysfunctional fistula
- vertigo, issues with sight, hearing, or perception
- or use painkillers within three hours before hemodialysis
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
No Intervention: control group
|
|
|
Experimental: study group
|
study group patients will view VR scene for 6 minutes before puncture .It involves a soothing nature experience and calming background music.
Patients in intervention group will not able to see the puncture procedure due to the VR glasses.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
change in patients pain scores
Time Frame: will be measured at baseline and immediately after intervention (after 6 minutes of VR distraction)
|
visual analogue scale which consists of a vertical line 100 mm long, one end of the line reads "No pain" and at the other is "Unbearable pain
|
will be measured at baseline and immediately after intervention (after 6 minutes of VR distraction)
|
|
change in patients anxiety scores
Time Frame: will be measured at baseline and immediately after intervention (after 6 minutes of VR distraction)
|
STAI includes two subscales with 20 items each that assess state and trait anxiety .The State Anxiety Scale requires individuals to describe their feelings at a specific moment under specific circumstances, while the Trait Anxiety Scale requires them to describe the way they feel in general.
|
will be measured at baseline and immediately after intervention (after 6 minutes of VR distraction)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
change in patients satisfaction score
Time Frame: will be measured at baseline and immediately after intervention (after 6 minutes of VR distraction)
|
. The patients will be asked to rate procedure satisfaction placing a mark on a 100-mm vertical visual analogue scale
|
will be measured at baseline and immediately after intervention (after 6 minutes of VR distraction)
|
|
change in patients heart rate
Time Frame: will be measured at baseline and immediately after intervention (after 6 minutes of VR distraction)
|
checklist will be used to assess heart rate after puncture
|
will be measured at baseline and immediately after intervention (after 6 minutes of VR distraction)
|
|
change in patients respiratory rate
Time Frame: will be measured at baseline and immediately after intervention (after 6 minutes of VR distraction)
|
checklist will be used to assess respiratory rate after puncture
|
will be measured at baseline and immediately after intervention (after 6 minutes of VR distraction)
|
|
change in patients systolic blood pressure
Time Frame: will be measured at baseline and immediately after intervention (after 6 minutes of VR distraction)
|
checklist will be used to assess systolic blood pressure after puncture
|
will be measured at baseline and immediately after intervention (after 6 minutes of VR distraction)
|
|
change in patients diastolic blood pressure
Time Frame: will be measured at baseline and immediately after intervention (after 6 minutes of VR distraction)
|
checklist will be used to assess diastolic blood pressure after puncture
|
will be measured at baseline and immediately after intervention (after 6 minutes of VR distraction)
|
|
change in patients Oxygen saturation (SpO2)
Time Frame: will be measured at baseline and immediately after intervention (after 6 minutes of VR distraction)
|
checklist will be used to assess Oxygen saturation after puncture
|
will be measured at baseline and immediately after intervention (after 6 minutes of VR distraction)
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- mansU
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.